Intra-Articular Injection of Rebamipide-Loaded Nanoparticles Attenuate Disease Progression and Joint Destruction in Osteoarthritis Rat Model: A Pilot Study
Sign Up to like & getrecommendations! Published in 2022 at "Cartilage"
DOI: 10.1177/19476035211069250
Abstract: Objective Rebamipide has antioxidant effects and is a drug with a local rather than systemic mechanism of action. Oxidative stress and inflammation in chondrocytes are the major factors contributing to the development and progression of… read more here.
Keywords: articular injection; rebamipide loaded; intra articular; rebamipide ... See more keywords
Potential Role of Rebamipide in Osteoclast Differentiation and Mandibular Condylar Cartilage Homeostasis
Sign Up to like & getrecommendations! Published in 2018 at "Current Rheumatology Reviews"
DOI: 10.2174/1573397113666171017113441
Abstract: Background: Temporomandibular joint osteoarthritis (TMJ-OA) is a degenerative disease that involves changes in subchondral bone and progressive degradation of cartilage. Currently, rebamipide, a gastroprotective drug, is administered to protect gastric mucosa and accelerate ulcer healing.… read more here.
Keywords: osteoclast differentiation; rebamipide; role rebamipide; potential role ... See more keywords
Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16010132
Abstract: Dry eye disease (DED) is one of the most common eye diseases caused by multiple factors. Rebamipide, which is currently used to treat peptic ulcer disease, was shown to enhance secretory function and modulate inflammation… read more here.
Keywords: administration; tolerability; tolerability pharmacokinetic; rebamipide ... See more keywords
Novel Sustained-Release Drug Delivery System for Dry Eye Therapy by Rebamipide Nanoparticles
Sign Up to like & getrecommendations! Published in 2020 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics12020155
Abstract: The commercially available rebamipide ophthalmic suspension (CA-REB) was approved for clinical use in patients with dry eye; however, the residence time on the ocular surface for the traditional formulations is short, since the drug is… read more here.
Keywords: rebamipide; drug; novel sustained; therapy ... See more keywords